Bridgefront Capital’s NovoCure NVCR Stock Holding History

Bridgefront Capital’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,659	Closed	-$202K	–	700
2025 Q3	$202K	Buy	+15,659	New	+$209K	0.06%	516
2024 Q4	–	Sell	-11,000	Closed	-$172K	–	725
2024 Q3	$172K	Sell	11,000 -5,102	-32%	-$92.5K	0.07%	467
2024 Q2	$276K	Buy	+16,102	New	+$283K	0.12%	321

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Bridgefront Capital's NVCR Position: Q4 2025 in Review

Bridgefront Capital sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 15,659 shares — an estimated $202K sold.

Bridgefront Capital first reported a position in NVCR in Q2 2024 and held it in 3 quarters. The position peaked at $276K in Q2 2024. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

Bridgefront Capital reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
Bridgefront Capital sold 15,659 NovoCure shares in Q4 2025, an estimated $202K.
Bridgefront Capital first reported a position in NovoCure in Q2 2024 and held it in 3 quarters.
Bridgefront Capital's NovoCure position peaked at $276K in Q2 2024.
238 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on Bridgefront Capital's 13F filing for Q4 2025, filed 13 Feb 2026.